WHO WE ARE
We are committed to providing patients with novel solutions to meet their healthcare needs.
Onconetix is a Nasdaq commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology.
The Company currently has Entadfi®, an FDA-approved, once-daily oral therapeutic for the treatment of benign prostatic hyperplasia (BPH), a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology. The company will continue to build the company in therapeutics, diagnostics, and services to clinicians and patients.